🧫
Proposed experiment from debate on TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small
active
experiment
Created: 2026-04-02T05:18:40
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-debate-7c7a8ed89fd3
🧫 Experiment Protocol
FalsificationNeurodegenerationG3BPcell_lineproposed
# Proposed experiment from debate on TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small
## Background and Rationale
This experiment tests the hypothesis that G3BP proteins contribute to TDP-43 pathological aggregation through mechanisms independent of canonical stress granule formation. While G3BP1/2 are well-established stress granule nucleators, recent evidence suggests they may also facilitate protein aggregation through direct protein-protein interactions or alternative phase separation pathways. The study employs TDP-43 aggregation models that bypass stress granule induction, including chronic low-level expression of aggregation-prone TDP-43 mutants (A315T, M337V) or treatment with aggregation-promoting conditions (hyperosmotic stress, proteasome inhibition) that don't trigger typical stress responses. Primary neuronal cultures or differentiated motor neuron-like cells will be used with G3BP1/2 knocked down via siRNA or genetically deleted using CRISPR. The experimental design specifically avoids sodium arsenite or heat shock protocols that induce stress granules, instead focusing on conditions where TDP-43 aggregation occurs through intrinsic propensity or cellular aging processes. Aggregation will be quantified using filter trap assays, immunocytochemistry for phosphorylated TDP-43, and biochemical fractionation to separate soluble from insoluble protein pools. This approach will reveal whether G3BP proteins have aggregation-promoting roles beyond their stress granule functions.
This experiment directly tests predictions arising from the following hypotheses:
- **Stress Granule Phase Separation Modulators**
- **Phase-Separated Organelle Targeting**
- **RNA Granule Nucleation Site Modulation**
- **Mitochondrial RNA Granule Rescue Pathway**
- **Axonal RNA Transport Reconstitution**
## Experimental Protocol
**Phase 1: Cell Culture Preparation (Days 1-3)**
• Maintain HEK293T, SH-SY5Y, and primary cortical neurons in appropriate media
• Transfect cells with TDP-43 wildtype, A315T, and M337V constructs using Lipofectamine 3000
• Generate stable G3BP1/G3BP2 knockout cell lines using CRISPR-Cas9 (n=3 clones per line)
• Validate knockout efficiency by Western blot and qRT-PCR
**Phase 2: G3BP Inhibition and TDP-43 Expression (Days 4-7)**
• Treat cells with G3BP inhibitors: C108 (10-50 μM), ISRIB (200 nM), or siRNA knockdown
• Express TDP-43 constructs for 24-48 hours to induce aggregation
• Avoid stress conditions (no arsenite, heat shock, or oxidative stress)
• Monitor cell viability using MTT assay and trypan blue exclusion
**Phase 3: TDP-43 Aggregation Analysis (Days 8-10)**
• Fix cells at 24, 48, and 72 hours post-transfection
• Perform immunofluorescence using anti-TDP-43 (1:500) and anti-G3BP1 (1:200) antibodies
• Quantify cytoplasmic TDP-43 aggregates >1 μm diameter per cell (n≥200 cells/condition)
• Assess nuclear TDP-43 clearance by measuring nuclear/cytoplasmic fluorescence ratio
• Perform filter trap assays to quantify insoluble TDP-43 aggregates
**Phase 4: Stress Response Assessment (Days 11-14)**
• Subject cells to mild physiological stresses: 42°C heat shock (30 min), 100 μM H2O2 (1 hour), 1 μM tunicamycin (4 hours)
• Measure cell survival by ATP luminescence and caspase-3/7 activity
• Analyze stress response gene expression (HSP70, CHOP, XBP1) by qRT-PCR
• Assess protein synthesis recovery using puromycin incorporation assay
**Phase 5: Alternative Nucleator Testing (Days 15-18)**
• Overexpress alternative stress granule nucleators: CAPRIN1, USP10, or UBAP2L
• Co-transfect with TDP-43 constructs in G3BP-deficient cells
• Quantify rescue of stress response functionality
• Measure formation of ribonucleoprotein granules using FISH for specific mRNAs
## Expected Outcomes
1. **TDP-43 aggregation will persist in G3BP-inhibited cells**, with ≥70% of transfected cells showing cytoplasmic aggregates regardless of G3BP status, demonstrating aggregation independence from stress granule machinery
2. **G3BP inhibition will impair cellular stress responses** by 40-60%, with reduced survival rates (p<0.01) and delayed protein synthesis recovery following physiological stress exposure
3. **Nuclear TDP-43 clearance will be unaffected by G3BP status**, maintaining similar nuclear depletion kinetics (50-70% reduction within 48 hours) across all treatment conditions
4. **Alternative stress granule nucleators will partially rescue stress responses** in G3BP-deficient cells, restoring 30-50% of normal stress tolerance when overexpressed
5. **Insoluble TDP-43 aggregate formation will show <20% difference** between G3BP-sufficient and G3BP-deficient conditions, measured by filter trap assay
6. **Cell viability under basal conditions will remain >85%** in G3BP-inhibited cells expressing TDP-43, indicating that aggregation toxicity is independent of G3BP-mediated pathways
## Success Criteria
• **Statistical significance threshold**: p<0.05 for all comparisons with n≥3 biological replicates and ≥200 cells analyzed per condition
• **TDP-43 aggregation independence**: <30% difference in aggregate formation between G3BP-sufficient and G3BP-deficient conditions across all TDP-43 variants
• **Stress response impairment**: ≥30% reduction in stress survival or protein synthesis recovery in G3BP-inhibited cells compared to controls
• **Knockout validation**: ≥90% reduction in G3BP1/G3BP2 protein levels confirmed by Western blot in all knockout clones used
• **Functional rescue criteria**: Alternative nucleators must restore ≥25% of normal stress response functionality to be considered functionally relevant
• **Reproducibility requirement**: Key findings must be replicated across at least 2 different cell types (HEK293T and neuronal cells) with consistent directional effects
PRIMARY OUTCOME
Quantification of insoluble TDP-43 aggregates using filter trap assays and biochemical fractionation in G3BP-deficient cells under non-stress granule inducing conditions compared to controls.
EXPECTED OUTCOMES
1. **TDP-43 aggregation will persist in G3BP-inhibited cells**, with ≥70% of transfected cells showing cytoplasmic aggregates regardless of G3BP status, demonstrating aggregation independence from stress granule machinery
2. **G3BP inhibition will impair cellular stress responses** by 40-60%, with reduced survival rates (p<0.01) and delayed protein synthesis recovery following physiological stress exposure
3. **Nuclear TDP-43 clearance will be unaffected by G3BP status**, maintaining similar nuclear depletion kinetics (50-70% reduction within 48 hours) across all treatment conditions
4. **Alternative stress granule nucleators will partially rescue stress responses** in G3BP-deficient cells, restoring 30-50% of normal stress tolerance when overexpressed
5. **Insoluble TDP-43 aggregate formation will show <20% difference** between G3BP-sufficient and G3BP-deficient conditions, measured by filter trap assay
6. **Cell viability under basal conditions will remain >85%** in G3BP-inhibited cells expressing TDP-43, indicating that aggregation toxicity is independent of G3BP-mediated pathways
SUCCESS CRITERIA
• **Statistical significance threshold**: p<0.05 for all comparisons with n≥3 biological replicates and ≥200 cells analyzed per condition
• **TDP-43 aggregation independence**: <30% difference in aggregate formation between G3BP-sufficient and G3BP-deficient conditions across all TDP-43 variants
• **Stress response impairment**: ≥30% reduction in stress survival or protein synthesis recovery in G3BP-inhibited cells compared to controls
• **Knockout validation**: ≥90% reduction in G3BP1/G3BP2 protein levels confirmed by Western blot in all knockout clones used
• **Functional rescue criteria**: Alternative nucleators must restore ≥25% of normal stress response functionality to be considered functionally relevant
• **Reproducibility requirement**: Key findings must be replicated across at least 2 different cell types (HEK293T and neuronal cells) with consistent directional effects
PROTOCOL
**Phase 1: Cell Culture Preparation (Days 1-3)**
• Maintain HEK293T, SH-SY5Y, and primary cortical neurons in appropriate media
• Transfect cells with TDP-43 wildtype, A315T, and M337V constructs using Lipofectamine 3000
• Generate stable G3BP1/G3BP2 knockout cell lines using CRISPR-Cas9 (n=3 clones per line)
• Validate knockout efficiency by Western blot and qRT-PCR
**Phase 2: G3BP Inhibition and TDP-43 Expression (Days 4-7)**
• Treat cells with G3BP inhibitors: C108 (10-50 μM), ISRIB (200 nM), or siRNA knockdown
• Express TDP-43 constructs for 24-48 hours to induce aggregation
• Avoid stress conditions (no arsenite, heat shock, or oxidative stress)
• Monitor cell viability using MTT assay and trypan blue exclusion
**Phase 3: TDP-43 Aggregation Analysis (Days 8-10)**
• Fix cells at 24, 48, and 72 hours post-transfection
• Perform immunofluorescence using anti-TDP-43 (1:500) and anti-G3BP1 (1:200) antibodies
• Quantify cytoplasmic TDP-43 aggregates >1 μm diameter per cell (n≥200 cells/condition)
• Assess nuclear TDP-43 clearance by measuring nuclear/cytoplasmic fluorescence ratio
• Perform filter trap assays to quantify insoluble TDP-43 aggregates
**Phase 4: Stress Response Assessment (Days 11-14)**
• Subject cells to mild physiological stresses: 42°C heat shock (30 min), 100 μM H2O2 (1 hour), 1 μM tunicamycin (4 hours)
• Measure cell survival by ATP luminescence and caspase-3/7 activity
• Analyze stress response gene expression (HSP70, CHOP, XBP1) by qRT-PCR
• Assess protein synthesis recovery using puromycin incorporation assay
**Phase 5: Alternative Nucleator Testing (Days 15-18)**
• Overexpress alternative stress granule nucleators: CAPRIN1, USP10, or UBAP2L
• Co-transfect with TDP-43 constructs in G3BP-deficient cells
• Quantify rescue of stress response functionality
• Measure formation of ribonucleoprotein granules using FISH for specific mRNAs
LINKED HYPOTHESES
Source: debate_extraction
🧫 Experiment Extras
ESTIMATED COST
$80,000
TIMELINE
5 months
MARKET PRICE
$0.46
STATUS
proposed
Scoring Dimensions
Prerequisite Graph (1 upstream, 7 downstream)
Prerequisites
⏳ s:**
- Temporal analysis showing mitochondrial defects precede other pathology
- Rescue exshould_completeBlocks (downstream)
s:**
- Single-cell RNA-seq to measure editing efficiency across different CNS cell types
-informsMechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FTDinformsExperiment Validation: In vitro ThT Assaymust_completePre-Symptomatic Detection and Intervention Timing in Genetic Prion Diseasemust_completeStress Granule Dysfunction Validation in Parkinson's Diseaseshould_completeC9orf72 Phenotype Divergence: ALS vs FTD Mechanism Studyshould_completeAxonal Transport Dysfunction Validation in Parkinson's Diseaseshould_completeMissions
🧠 Neurodegeneration▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.